Date: 2014-07-02
Type of information: Distribution agreement
Compound: ConfirmMDx® for Prostate Cancer
Company: MDxHealth (Belgium) Miraca Life Sciences (USA - CA)
Therapeutic area: Diagnostic - Cancer - Oncology
Type agreement: distribution
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or \"halo\" associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular \"halo\" around a cancer lesion can be present despite having a normal appearance under the microscope.
Disease: prostate cancer
Details: * On July 2, 2014, MDxHealth, a Belgian molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced that it has entered into an agreement with Miraca Life Sciences (MLS), US largest independent anatomic pathology lab, to promote MDxHealth\'s ConfirmMDx® for Prostate Cancer test. Serving more than 5,500 patients each day, Miraca Life Sciences is a national leader in providing academic-caliber pathology services in the fields of dermatology, hematology, gastroenterology and urology.
Financial terms:
Latest news:
